CL2023001534A1 - Compuesto de heteroarilcarboxamida - Google Patents

Compuesto de heteroarilcarboxamida

Info

Publication number
CL2023001534A1
CL2023001534A1 CL2023001534A CL2023001534A CL2023001534A1 CL 2023001534 A1 CL2023001534 A1 CL 2023001534A1 CL 2023001534 A CL2023001534 A CL 2023001534A CL 2023001534 A CL2023001534 A CL 2023001534A CL 2023001534 A1 CL2023001534 A1 CL 2023001534A1
Authority
CL
Chile
Prior art keywords
antibody
compound
heteroarylcarboxamide
cancer
treatment
Prior art date
Application number
CL2023001534A
Other languages
English (en)
Inventor
Takashi Kamikubo
Hideyuki Watanabe
Yohei Seki
Keiichiro Okuyama
Osamu Ikeda
Hiroshi Tomiyama
Yoshinori Iwai
Akihiko Nakamura
Kozo Miyasaka
Akio Kamikawa
Takuya Washio
Original Assignee
Kotobuki Pharmaceutical Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Pharmaceutical Co Ltd, Astellas Pharma Inc filed Critical Kotobuki Pharmaceutical Co Ltd
Publication of CL2023001534A1 publication Critical patent/CL2023001534A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1. Los presentes inventores han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1, y han confirmado que un compuesto de heteroarilcarboxamida tiene un efecto inhibidor ? de DGK (DGKzeta), lo que conduce a la finalización de la presente invención. El compuesto de heteroarilcarboxamida de la presente invención tiene un efecto inhibidor ? de DGK y puede usarse como un agente terapéutico para el tratamiento de cáncer relacionado con la activación de células inmunitarias o cáncer resistente a la terapia con anticuerpo anti-PD-1/anticuerpo anti-PD-L1.
CL2023001534A 2020-11-30 2023-05-29 Compuesto de heteroarilcarboxamida CL2023001534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020197899 2020-11-30

Publications (1)

Publication Number Publication Date
CL2023001534A1 true CL2023001534A1 (es) 2023-11-10

Family

ID=81754515

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001534A CL2023001534A1 (es) 2020-11-30 2023-05-29 Compuesto de heteroarilcarboxamida

Country Status (18)

Country Link
US (2) US20240043403A1 (es)
EP (1) EP4253373A1 (es)
JP (1) JP7397452B2 (es)
KR (1) KR20230116838A (es)
CN (1) CN116528864A (es)
AR (1) AR124172A1 (es)
AU (1) AU2021389180A1 (es)
CA (1) CA3203285A1 (es)
CL (1) CL2023001534A1 (es)
CO (1) CO2023008271A2 (es)
CR (1) CR20230415A (es)
DO (1) DOP2023000107A (es)
EC (1) ECSP23048974A (es)
IL (1) IL303209A (es)
MX (1) MX2023006318A (es)
PE (1) PE20231986A1 (es)
TW (1) TW202229256A (es)
WO (1) WO2022114164A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
WO2023248109A1 (en) 2022-06-20 2023-12-28 Astellas Pharma Inc. Methods for treating patients with locally advanced and/or metastatic solid tumors using a dgk zeta inhibitor
WO2024108100A1 (en) * 2022-11-18 2024-05-23 Incyte Corporation Heteroaryl fluoroalkenes as dgk inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381401B2 (en) 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
BRPI0607308A2 (pt) 2005-01-25 2009-08-25 Synta Pharmaceuticals Corp compostos, composições farmacêuticas e usos dos referidos compostos
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
KR20090004976A (ko) 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
MX2009004786A (es) 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
MX2020002399A (es) 2017-09-06 2020-07-22 Propellon Therapeutics Inc Inhibidores del enlace proteína-proteína de wdr5.
CA3104654A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz

Also Published As

Publication number Publication date
JP7397452B2 (ja) 2023-12-13
US20240101532A1 (en) 2024-03-28
ECSP23048974A (es) 2023-07-31
PE20231986A1 (es) 2023-12-12
CR20230415A (es) 2023-09-08
EP4253373A1 (en) 2023-10-04
KR20230116838A (ko) 2023-08-04
CO2023008271A2 (es) 2023-07-21
CN116528864A (zh) 2023-08-01
DOP2023000107A (es) 2023-07-16
MX2023006318A (es) 2023-06-14
WO2022114164A1 (ja) 2022-06-02
AR124172A1 (es) 2023-02-22
CA3203285A1 (en) 2022-06-02
IL303209A (en) 2023-07-01
AU2021389180A1 (en) 2023-06-29
US20240043403A1 (en) 2024-02-08
JPWO2022114164A1 (es) 2022-06-02
TW202229256A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
CL2022001752A1 (es) Compuesto de piridazinil-tiazolcarboxamida
CL2023001534A1 (es) Compuesto de heteroarilcarboxamida
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO2019008487A2 (es) Compuesto de quinazolina
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
ECSP19082194A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
UY35082A (es) Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer
BR112018002530A2 (pt) combinações e usos e tratamentos destas
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo
BR112022022713A2 (pt) Dosagem e administração de anticorpo anti-ctla-4 ativável
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
SV2016005308A (es) Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol